Clinical investigation of TROP-2 as an independent biomarker and potential therapeutic target in colon cancer

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 4364-4369

  Zhao, Peng ^a   Yu, Hai Zheng ^b   Cai, Jian Hui ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNITED UNIVERSITY   (China)

Author keywords

Colon cancer; Dukes stage; Metastasis; Therapeutic target; Trophoblast cell surface marker 2

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE PROTEIN; HUMAN TROPHOBLAST CELL SURFACE MARKER PROTEIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DIFFERENTIATION; TUMOR INVASION; ADENOCARCINOMA; COLON; COLONIC NEOPLASMS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SECONDARY;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CELL ADHESION MOLECULES; COLON; COLONIC NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY;

EID: 84935463889     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3900     Document Type: Article

References (28)

1. Chiang EP, Tsai SY, Kuo YH, et al: Caffeic Acid Derivatives Inhibit the Growth of Colon Cancer: Involvement of the PI3-K/Akt and AMPK Signaling Pathways. PloS One 9:e99631, 2014.
2. Boncheva V, Bonney SA, Brooks SE, et al: New targets for the immunotherapy of colon cancer-does reactive disease hold the answer? Cancer Gene Ther 20:157-168, 2013.
3. Carethers JM, Murali B, Yang B, et al: Influence of Race on Microsatellite Instability and CD8+ T Cell Infiltration in Colon Cancer. PloS One 9:e100461, 2014.
4. Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, Demirelli F and Serdengecti S: Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumour Biol 34:2233-2239, 2013.
5. Mayer RJ, Garnick MB, Steele GD Jr. and Zamcheck N: Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 42:1428-1433, 1978.
6. Petrioli R, Licchetta A, Roviello G, et al: CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest 30:65-71, 2012.
7. Van den Eynden GG, Majeed AW, Illemann M, et al: The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res 73:2031-2043, 2013.
8. Fong D, Spizzo G, Gostner JM, et al: TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Modern Pathol 21:186-191, 2008.
9. Pak MG, Shin DH, Lee CH and Lee MK: Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol 10:53, 2012.
10. Fong D, Moser P, Krammel C, et al: High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 99:1290-1295, 2008.
11. Mühlmann G, Spizzo G, Gostner J, et al: TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 62:152-158, 2009
12. Zhang L, Zhou W, Velculescu VE, et al: Gene expression profiles in normal and cancer cells. Science 276:1268-1272, 1997
13. Fornaro M, Dell'Arciprete R, Stella M, et al: Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 62:610-618, 1995
14. El Sewedy T, Fornaro M and Alberti S: Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer 75:324-330, 1998.
15. Coldren CD, Helfrich BA, Witta SE, et al: Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4:521-528, 2006.
16. Bignotti E, Todeschini P, Calza S, et al: Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 46:944-953, 2010.
17. Ambrogi F, Fornili M, Boracchi P, et al: Trop-2 is a determinant of breast cancer survival. PloS One 9:e96993, 2014
18. Cubas R, Li M, Chen C and Yao Q: Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 1796:309-314, 2009
19. Varughese J, Cocco E, Bellone S, et al: Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer 117:3163-3172, 2011.
20. Ripani E, Sacchetti A, Corda D and Alberti S: Human Trop-2 is a tumor-associated calcium signal transducer. IntJ Cancer 76:671-676, 1998.
21. Trerotola M, Li J, Alberti S and Languino LR: Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the beta1 integrin-RACK1 axis. J Cell Physiol 227:3670-3677, 2012.
22. Trerotola M, Cantanelli P, Guerra E, et al: Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32:222-233, 2013.
23. Huang HY Role of TROP2 in cancer and as potential therapeutic target. Zhonghua Bing Li Xue Za Zhi 42:860-863, 2013 (Article in Chinese).
24. Lu J, Izvolsky KI, Qian J and Cardoso WV: Identification of FGF10 targets in the embryonic lung epithelium during bud morphogenesis. J Biol Chem 280:4834-4841, 2005
25. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J and Witte ON: Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev 26:2271-2285, 2012.
26. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP and Witte ON: Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc the Natl Acad Sci USA 105:20882-20887, 2008.
27. Antonic V, Stojadinovic A, Kester KE, Weina PJ, Brücher BL, Protic M, Avital I, and Izadjoo M: Significance of infectious agents in colorectal cancer development. J Cancer 4:227-240, 2013.
28. Messick CA, Church J, Casey G and Kalady MF: Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum 52:1535-1541, 2009